CARMIEL, Israel, Aug. 30, 2019-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of.
Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American - Nasdaq
Read More
CARMIEL, Israel, Aug. 30, 2019-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of.
No comments:
Post a Comment